Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

By sjmartinez • March 5, 2025

Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, Choy EH, Peyrin-Biroulet L, Schmalzing M, Tanaka Y, Ten Cate H, Westhovens R, van der Woude CJ, Ekoka Omoruyi EV, Faes M, Masior T, Van Hoek P, Watson C, Rudolph C, Stallmach A. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 2025 Mar 4;11(1):e005033. doi: 10.1136/rmdopen-2024-005033. PMID: 40037922; PMCID: PMC11881192.

Tags: Antirheumatic Agents, Arthritis, Inflammation, Publications, Rheumatoid, Rheumatology

Global, Regional, and National Burden of Myocarditis and Its Impairment, 1990-2023

GBD 2023 Myocarditis Collaborators. Global, Regional, and National Burden of Myocarditis and Its Impairment, 1990-2023. J Am Coll Cardiol. 2026 Oct 13;88(15):1730-1760. doi: 10.1016/j.jacc.2026.07.039. Epub[...]

Moyamoya disease presenting as galactorrhea

Noveir SD, Agrawal N. Moyamoya disease presenting as galactorrhea. JCEM Case Rep. 2026 Oct 13;4(11):luag296. doi: 10.1210/jcemcr/luag296. PMID: 42871260; PMCID: PMC13658269.

Muscle-lung crosstalk in COPD: how exercise training modulates protein metabolism and inflammation in experimental COPD models

Abbasi A, Vieira RP, Degobbi T Q S Lopes F. Muscle-lung crosstalk in COPD: how exercise training modulates protein metabolism and inflammation in experimental COPD[...]